NCT05826691

Brief Summary

Rationale: A variety of surgical techniques have been described for surgical treatment of male LUTS because of BPH, which has different outcomes and may result in adverse events regarding ejaculatory function and erection, resulting in a negative impact on QOL on short- and mid-term follow-ups. Objective: To compare outcomes of BPH surgery using a conventional versus ejaculation preserving technique on QOL-related aspects with emphasis on ejaculatory and erectile function. Study design: This study is a prospective longitudinal multi-center trial to compare the ejaculatory and erectile function outcomes between conventional and ejaculation preserving BPH surgical procedures/techniques. Baseline characteristics will be recorded, as well as short and mid-term follow-up. Study population: The study population comprises patients who will undergo BPH surgery in the participating centers. Intervention: All patients will undergo BPH surgery (including but not restricted to Monopolar / Bipolar Transurethral resection of the prostate (TURP), photo vaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)). Main study parameters/endpoints: Primary endpoint is to compare the baseline to the short-term (3 months) and mid-term (6 months) ejaculation function and QoL outcomes. The secondary endpoint is the short and mid-term erection function and QoL outcomes compared to baseline. Nature and extent of the burden and risks associated with participation, benefit, and group relatedness: Patients' burden and risk associated with participating in this trial do not differ among surgical procedures or techniques used. In all groups, patients will undergo a BPH surgery and will be followed for six months at 3 visits.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2021

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

March 22, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 24, 2023

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2023

Completed
Last Updated

April 24, 2023

Status Verified

April 1, 2023

Enrollment Period

1.7 years

First QC Date

March 22, 2023

Last Update Submit

April 12, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • Preservation of QOL after surgery for BPH

    QOL will be assessed before and after by means of validated SF-12 questionnaire

    Baseline to 6 months after surgery

  • Preservation of sexual function after surgery for BPH

    Sexual function will be assessed before and after by means of IIEF-5 validated questionnaire

    Baseline to 6 months after surgery

  • Preservation of ejaculatory function after surgery for BPH

    Ejaculatory function will be assessed before and after by means of MSHQ-EjD-SF validated questionnaire

    Baseline to 6 months after surgery

  • Preservation of voiding function after ejaculation preserving BPH surgery

    LUTS will be assessed before and after by means of IPSS validated questionnaire

    Baseline to 6 months after surgery

Secondary Outcomes (4)

  • Comparison of post-operative complications among the different disobstructive methods

    From the day of the operastion up to 90 days

  • Comparison objective outcomes of uroflowmetry Qmax parameter (ml/sec) in relation to outcomes in preservation of ejaculation and unpreserved surgery

    Baseline to 6 months after surgery

  • Comparison residual urine volumes (Post-voided residual urine, ml) by ultrasound measurement in relation to outcomes in preservation of ejaculation and unpreserved surgery

    Baseline to 6 months after surgery

  • Comparison changes in erectile function between conventional and preserving ejaculatory techniques by using IIEF-5 validated questionnarie

    Baseline to 6 months after surgery

Study Arms (1)

Patients required prostate surgery for LUTS

Patients with LUTS attributable to bladder outlet obstruction because BPH

Procedure: Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).

Interventions

Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction

Also known as: Open prostatectomy
Patients required prostate surgery for LUTS

Eligibility Criteria

Age40 Years - 90 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsBecause of the nature of prostatic obstruction only males or individuals with prostate gland can be included
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult male patients, complaining of LUTS who require surgery because BPH

You may qualify if:

  • Has signed informed consent
  • Is aged 40 years or older
  • With or without erectile function and/or antegrade ejaculation
  • No limitation for prostate volume
  • Height 150-250 cm
  • Weight 40-150 kg
  • Age 40-90 years old
  • PSA 0.1-30 ng/ml
  • Creatinine 0.5-4mg/dl

You may not qualify if:

  • History of BPH surgery
  • History of pelvic radiation
  • History of chronic prostatitis or chronic pelvic pain syndrome
  • History of urethral stricture
  • History of bladder neck contracture
  • Has or has had tumors in the urinary tract
  • Has or has had prostate cancer
  • Has had previous irradiation of the pelvis
  • Has bladder stone
  • Has urinary tract infection (UTI)
  • Has chronic UTI
  • Has neurogenic disorder
  • Has conditions associated with a risk of poor protocol compliance
  • Has participation in other clinical studies with investigational drugs either concurrently or within the last 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istanbul Medipol University

Istanbul, 34214, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Sexual Dysfunction, PhysiologicalEjaculatory DysfunctionLower Urinary Tract SymptomsErectile Dysfunction

Interventions

Transurethral Resection of Prostate

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital DiseasesGenital Diseases, MaleMale Urogenital DiseasesUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSexual Dysfunctions, PsychologicalMental Disorders

Intervention Hierarchy (Ancestors)

ProstatectomyUrologic Surgical Procedures, MaleUrologic Surgical ProceduresUrogenital Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Johan J de la Rosette, MD PhD

    Medipol University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Vahit Guzelburc, MD FEBU FACS

CONTACT

Johan J de la Rosette, MD PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Urology

Study Record Dates

First Submitted

March 22, 2023

First Posted

April 24, 2023

Study Start

September 1, 2021

Primary Completion

June 1, 2023

Study Completion

September 30, 2023

Last Updated

April 24, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations